Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer-Reference-Cited by-同舟云学术

Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer

Published:2021-08-25 Issue:4 Volume:88 Page:354-360
ISSN:1345-4676
Container-title:Journal of Nippon Medical School
language:en
Short-container-title:J Nippon Med Sch

Author:

Hayashi Yuji¹,Takei Hiroyuki²,Saito Tsuyoshi¹,Kai Toshihiro³,Inoue Kenichi⁴,Kurosumi Masafumi⁵,Ninomiya Jun⁶,

Affiliation:

1. Department of Breast Surgery, Japanese Red Cross Saitama Hospital

2. Division of Breast Surgery, Saitama Cancer Center

3. Shintoshin Ladies' MammoClinic

4. Division of Breast Oncology, Saitama Cancer Center

5. Department of Pathology, Kameda Kyobashi Clinic

6. Ninomiya Hospital

Publisher

Medical Association of Nippon Medical School

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jnms/88/4/88_JNMS.2021_88-509/_pdf

Reference22 articles.

1. 1. Iwase H. Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor. Int J Clin Oncol. 2015;20:249-52. doi: 10.1007/s10147-015-0795-6

2. 2. Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110:244-54. doi: 10.1002/cncr.22789

3. 3. Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23:3069-74. doi: 10.1093/annonc/mds132

4. 4. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808-16. doi: 10.1200/JCO.2001.19.18.3808

5. 5. Smith IE, Dowsett M, Ebbs SR, et al. IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination:the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108-16.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Endocrine Therapy for Operable Breast Cancer: A Retrospective Analysis of Real-World Use;Journal of Nippon Medical School;2021-10-25